10-K: Glucotrack Advances CBGM Amid Going Concern, Nasdaq Risks

Glucotrack, Inc. reports progress on its implantable continuous blood glucose monitor and recent financing, but faces substantial doubt about its ability to continue as a going concern and ongoing Nasdaq listing challenges.

Summary

• Glucotrack is developing an implantable continuous blood glucose monitor (CBGM) for diabetes patients, having ceased development of its first-generation non-invasive device in 2023.
• The company completed a first-in-human acute study in 2025, demonstrating positive device performance and safety, with results presented at medical conferences.
• A long-term multicenter feasibility study in Australia was closed to incorporate product updates and protocol modifications, with plans to expedite discussions with the FDA for a U.S. clinical trial program in H2 2026.
• Net loss for 2025 was $19.388 million, an improvement from $22.579 million in 2024, but the company has an accumulated deficit of $151.838 million.
• Cash and cash equivalents stood at $7.383 million as of December 31, 2025, with net cash provided by financing activities totaling $17.043 million in 2025.
• The company successfully obtained ISO 13485 certification in 2024 and passed its annual audit in 2025 without major nonconformities.
• Glucotrack issued three new U.S. patents in late 2025 related to glucose sensing technology and published one international patent application for integrated spinal cord stimulation and glucose monitoring.
• The company faced multiple Nasdaq listing compliance issues in 2024 and 2025, necessitating two reverse stock splits (1-for-20 in Feb 2025, 1-for-60 in June 2025) to regain compliance with the Bid Price Rule.
• Management identified material weaknesses in internal control over financial reporting as of December 31, 2025, related to insufficient accounting personnel, segregation of duties, and IT general controls, with remediation efforts underway.
• Peter C. Wulff resigned as Chief Financial Officer effective March 31, 2026, and will receive $112,500 in severance payments.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly speculative filing. While there's promising R&D progress and successful financing, the significant going concern doubt, internal control weaknesses, and ongoing Nasdaq listing risks present substantial challenges and uncertainty for investors.

Positives

• Successful completion of a first-in-human acute study for the Glucotrack CBGM in 2025, meeting safety endpoints and demonstrating performance and accuracy similar to animal studies.
• Demonstrated continuous glucose sensing in the epidural space, potentially enabling integrated chronic disease management.
• Achieved ISO 13485 certification in 2024 and successfully passed the 2025 annual audit without major nonconformities, indicating strong quality management systems.
• Strengthened intellectual property portfolio with the issuance of three new U.S. patents in late 2025 and the publication of one international patent application.
• Net loss decreased to $19.388 million in 2025 from $22.579 million in 2024.
• Successfully raised $17.043 million in net proceeds from financing activities in 2025, including ATM sales, a registered direct offering, and a private placement.
• Regained compliance with Nasdaq's Bid Price Rule and other listing rules as of November 5, 2025.

Negatives

• History of operating losses and an accumulated deficit of $151.838 million as of December 31, 2025.
• Independent registered public accounting firm's report contains an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern.
• Net cash used in operating activities increased to $15.240 million in 2025 from $12.490 million in 2024.
• The long-term multicenter feasibility study in Australia was closed due to product updates and protocol modifications, delaying clinical progress.
• Glucotrack CBGM is not yet approved for commercial sale in the U.S. or internationally, requiring significant future clinical trials and regulatory approvals.
• Identified material weaknesses in internal control over financial reporting as of December 31, 2025, indicating a risk of material misstatements.
• Nasdaq has proposed a new $5 million market value of listed securities requirement, which the company currently does not meet, posing a risk of imminent delisting if approved.
• Significant shift from $8.050 million in other income in 2024 to $3.298 million in other expense in 2025, primarily due to changes in fair value of derivative liabilities and reduced gains from debt settlement/equity issuance.
• Peter C. Wulff, Chief Financial Officer, resigned effective March 31, 2026, which could impact financial management stability.

Risks

• Ability to generate material revenues or become profitable in the near future, given a history of operating losses and an accumulated deficit of $151.8 million.
• Ability to raise additional capital on acceptable terms, with the independent auditor expressing substantial doubt about the company's ability to continue as a going concern.
• Dilution to existing stockholders from future equity or convertible debt offerings.
• Economic crises and market instability adversely affecting demand for products or ability to secure funds.
• Failure to obtain regulatory approval or clearance for Glucotrack CBGM, which is currently under preclinical development and requires significant, expensive, and uncertain clinical trials.
• Competition from more effective, safer, or less expensive products from established medical device companies like Abbott, DexCom, Medtronic, and Senseonics.
• Technological advances or new therapies (e.g., GLP-1 drugs) rendering Glucotrack CBGM obsolete or less competitive.
• Delays or cessation of product development activities and clinical trials due to funding, patient recruitment, regulatory approvals, or unforeseen safety issues.
• Limitations on manufacturing and marketing due to terms of regulatory clearances or ongoing regulatory compliance requirements.
• Lack of market acceptance for products even if regulatory approval is received.
• Inadequate insurance coverage for product liability lawsuits, which could result in substantial liabilities.
• Failure to attract and retain key management and scientific personnel.
• Reliance on third parties for manufacturing and supply, posing risks of production delays, quality issues, and increased costs.
• Economic, political, regulatory, and other risks associated with international operations, including restrictions from Israeli Innovation Authority funding.
• Potential delisting from Nasdaq due to failure to meet continued listing requirements, including a newly proposed $5 million market value of listed securities threshold.
• Material weaknesses in internal control over financial reporting, risking material misstatements and impacting investor confidence.
• Volatility in the market price and trading volume of common stock.
• Dilutive effect of a substantial number of outstanding convertible securities (warrants).
• Provisions in charter documents and Delaware law that may discourage acquisitions or prevent changes in management.
• Inability to obtain and enforce patent protection for products, or infringement on third-party intellectual property rights.
• Security threats to information technology infrastructure, exposing the company to liability and reputational damage.
• Inability to protect the confidentiality of proprietary information and know-how.
• Claims that employees or consultants have wrongfully used or disclosed alleged trade secrets.

Future Outlook

The company expects to file its Investigational Device Exemption (IDE) submission with the FDA in the second quarter of 2026 and aims to launch its U.S. clinical trial program in the second half of 2026, subject to FDA approval. It anticipates increased research and development expenses in 2026 and beyond due to expanding clinical trial activities and hiring additional personnel. The company plans to continue financing operations through equity and/or debt financings, license agreements, or collaborative arrangements.

Management Comments

• Our technology, if successful, has the potential to be more accurate, more convenient and have a longer duration than other implantable glucose monitors that are either in the market or currently under development.
• The epidural sensing approach may enable integrated chronic disease management with one system that provides dual benefits of pain relief and glucose monitoring.
• Management intends to continue remediation efforts for internal control weaknesses during fiscal year 2026; however, these initiatives may not fully remediate all material weaknesses in our internal control over financial reporting.

Industry Context

StockSavvy.ai notes that Glucotrack operates in a highly competitive and rapidly evolving continuous glucose monitoring (CGM) market dominated by established players like Abbott Laboratories, DexCom, and Medtronic, which offer transcutaneous systems. The company's focus on a long-term implantable CBGM with an intravascular approach aims to address existing barriers to CGM adoption, such as device discomfort and frequent replacement, differentiating it from most current market offerings. While Senseonics Holdings, Inc. offers an implantable CGM, Glucotrack's technology aims for effectively zero lag time in glucose measurement, a potential advantage over interstitial fluid-based systems. The increasing use of GLP-1 drugs for diabetes and obesity treatment presents a potential competitive threat, particularly for Type 2 diabetes patients not dependent on insulin, which could impact Glucotrack's market penetration.

Comparison to Industry Standards

• Glucotrack's Glucotrack CBGM aims for a 2-3 year implant life, significantly longer than commercially available transcutaneous CGM systems from Abbott (e.g., FreeStyle Libre 3), DexCom (e.g., G7), and Medtronic (e.g., Guardian 4), which have sensor longevities of 7-15 days.
• The company's intravascular approach for CBGM aims for effectively zero lag time in glucose measurements, contrasting with interstitial fluid-based CGM systems (including those from Abbott, DexCom, Medtronic, and Senseonics) which typically have a 15-20 minute lag behind blood glucose readings.
• Unlike the Senseonics implantable CGM, which requires daily adhesive for a wearable smart transmitter and daily fingerstick calibrations after an initial period, Glucotrack's CBGM aims for no additional wearable component and minimal calibration.
• Glucotrack's technology is not currently integrated with automated insulin delivery systems, a feature increasingly offered by competitors like Medtronic, Abbott, and DexCom.

Management Changes

Corporate Governance

Legal Proceedings

• Not presently a party to any material litigation, but may become involved in litigation matters arising in the ordinary course of business.

Related Party Transactions

• Intellectual Property Purchase Agreement (October 7, 2022) with Paul V. Goode (CEO), where he assigned IP related to the Glucotrack CBGM in exchange for cash ($1) and up to 167 shares of Common Stock (plus true-up shares) upon milestone achievement. 42 shares were earned in March 2025.
• April 2024 Private Placement included participation from certain members of executive management, Board of Directors, and existing shareholders.
• June 27, 2024, Private Placement involved unsecured promissory notes and warrants with certain officers, directors, and existing investors (June 27 Investors).
• July 18, 2024, Private Placement involved convertible promissory notes with three directors and one member of executive management (July 18 Investors).
• July 30, 2024, Private Placement involved a secured convertible promissory note and three warrant agreements with an existing investor (July 30 Holder), who is controlled by a director of the company.
• Lease agreement (February 19, 2024) with Tapsak Enterprises LLC, wholly owned by Mark Tapsak (Chief Scientific Officer), for office and research laboratory space, with payments of $30,000 in 2025 and $25,000 in 2024.

Stakeholder Impact

• Shareholders face significant dilution risk from future capital raises and warrant exercises. The company's going concern doubt and Nasdaq delisting risk could severely impact share price and liquidity. Material weaknesses in internal controls also pose a risk to financial transparency and investor confidence.
• Employees' job security is directly impacted by the company's ability to continue as a going concern. Stock-based compensation is a key incentive, but its value is tied to the volatile stock price and overall company performance.
• Future customers could benefit from a new, potentially more convenient and accurate diabetes management solution if Glucotrack CBGM is successfully developed and commercialized. Delays in clinical trials or regulatory approval would delay product availability.
• Creditors face risks to the repayment of debt obligations, including the promissory note issued in September 2025, due to the company's going concern doubt and reliance on future financing.
• Suppliers and partners, particularly third-party manufacturers and contract research organizations, are critical to Glucotrack's product development and commercialization timelines, making their operational stability and compliance essential.

Next Steps

• Expedite discussions with the U.S. Food and Drug Administration (FDA) regarding the planned U.S. clinical trial program.
• File Investigational Device Exemption (IDE) submission with the FDA in the second quarter of 2026.
• Launch U.S. clinical trial program in the second half of 2026, subject to FDA approval.
• Continue remediation efforts for material weaknesses in internal control over financial reporting during fiscal year 2026.
• Evaluate additional patent filings as technology development progresses.
• Assess the current reimbursement landscape for cardiovascular devices to craft a suitable reimbursement strategy for Glucotrack CBGM.
• Consider alternative markets for commercialization that can leverage both FDA and CE Mark approvals.
• Seek stockholder approval for the Equity Line of Credit (ELOC) to issue Purchase Shares in excess of the Exchange Cap.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by substantial doubt about its ability to continue as a going concern, a large accumulated deficit, and increasing cash burn from operations. Despite some R&D progress and recent financing, the closure of a key clinical study and ongoing Nasdaq delisting risks (including a new proposed market value threshold) create significant uncertainty. Material weaknesses in internal controls further undermine confidence. The high level of risk, coupled with the speculative nature of its single product candidate and intense competition, suggests a strong sell recommendation for investors.

Keywords

Implantable Continuous Glucose Monitor, CBGM, Diabetes Management, Medical Device, SEC Filing, Nasdaq Listing, Clinical Trials, Regulatory Approval, Financial Performance, Warrants, Capital Raise, Intellectual Property, Corporate Governance, Glucotrack